In simulated patients with type 2 diabetes, liraglutide 1.8 mg projected improved survival versus glimepiride; the abstract lists 30-year survival benefits of 16.5% (1.8 mg), 13.6% (1.2 mg) and 7.3% (glimepiride).
In plain wordsA computer model projected better survival with liraglutide 1.8 mg than with glimepiride in type 2 diabetes.
- Peptide
- Liraglutide
- Outcome
- IncreaseSurvival after 30 years
- Study
n: not reported in source
CORE Diabetes Model- Comparator
- Glimepiride 8 mg/day
- Outcome group
- Mortality · Whole body
- Studied dose
- 1.8 mg/day · 10, 20 and 30 years (simulated)As given in this study.
Measurements
- 30-year survival benefit
- 16.5%
- liraglutide 1.8 mg
- 30-year survival benefit
- 7.3%
- glimepiride
Source sentences
Simulations predicted improved survival for liraglutide 1.8 and 1.2 mg at all three time points compared with glimepiride. Survival benefits were greatest after 30 years of follow-up: 16.5%, 13.6%, and 7.3%, respectively.
2 context sentences(design, population, supporting numbers)
Mathematic simulation using the validated Center for Outcomes Research (CORE) Diabetes Model, calibrated to baseline patient characteristics from a short-term, randomized, controlled trial of liraglutide and glimepiride monotherapies (Liraglutide Effect and Action in Diabetes [LEAD]-3 trial) and usi…
The patients in the LEAD-3 trial were randomly assigned to monotherapy with liraglutide 1.2 mg/day (251 patients), liraglutide 1.8 mg/day (247 patients), or glimepiride 8 mg/day (248 patients).